Syndromes of Severe Insulin Resistance and/or Lipodystrophy

Genetic Diagnosis of Endocrine Disorders: Second Edition

Volumn , Issue , 2015, Pages 307-324

  Semple, Robert K ^a   Savage, David B ^a   Brierley, Gemma V ^a   O'Rahilly, Stephen ^a  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

Author keywords

AGPAT2; BSCL2; Diabetes; Hyperandrogenism; Insulin receptor; Insulin resistance; Lamin; Lipodystrophy; PCOS; PPAR

Indexed keywords

EID: 85141227798     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-800892-8.00022-1     Document Type: Chapter

References (62)

1. Warram J.H., Martin B.C., Krolewski A.S., Soeldner J.S., Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990, 113:909-915.
2. Kahn C.R., Flier J.S., Bar R.S., Archer J.A., Gorden P., Martin M.M., Roth J. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976, 294:739-745.
3. Barbieri R.L., Ryan K.J. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983, 147:90-101.
4. Semple R.K., Cochran E.K., Soos M.A., Burling K.A., Savage D.B., Gorden P., O'Rahilly S. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008, 31:977-979.
5. Semple R.K., Soos M.A., Luan J., Mitchell C.S., Wilson J.C., Gurnell M., Cochran E.K., Gorden P., Chatterjee V.K., Wareham N.J., O'Rahilly S. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 2006, 91:3219-3223.
6. Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L., Jackson S., Vottero A., Kanabar D., Charlton-Menys V., Durrington P., Soos M.A., Carpenter T.A., Lomas D.J., Cochran E.K., Gorden P., O'Rahilly S., Savage D.B. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009, 119:315-322.
7. George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S., Wilson J.C., Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L., Dunger D.B., Barford D., Umpleby A.M., Wareham N.J., Davies H.A., Schafer A.J., Stoffel M., O'Rahilly S., Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004, 304:1325-1328.
8. Thauvin-Robinet C., Auclair M., Duplomb L., Caron-Debarle M., Avila M., St-Onge J., Le Merrer M., Le Luyer B., Heron D., Mathieu-Dramard M., Bitoun P., Petit J.M., Odent S., Amiel J., Picot D., Carmignac V., Thevenon J., Callier P., Laville M., Reznik Y., Fagour C., Nunes M.L., Capeau J., Lascols O., Huet F., Faivre L., Vigouroux C., Riviere J.B. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet 2013, 93:141-149.
9. Dyment D.A., Smith A.C., Alcantara D., Schwartzentruber J.A., Basel-Vanagaite L., Curry C.J., Temple I.K., Reardon W., Mansour S., Haq M.R., Gilbert R., Lehmann O.J., Vanstone M.R., Beaulieu C.L., Majewski J., Bulman D.E., O'Driscoll M., Boycott K.M., Innes A.M. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet 2013, 93:158-166.
10. Chudasama K.K., Winnay J., Johansson S., Claudi T., Konig R., Haldorsen I., Johansson B., Woo J.R., Aarskog D., Sagen J.V., Kahn C.R., Molven A., Njolstad P.R. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet 2013, 93:150-157.
11. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004, 350:1220-1234.
12. Seip M., Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996, 413:2-28.
13. Garg A., Fleckenstein J.L., Peshock R.M., Grundy S.M. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 1992, 75:358-361.
14. Pardini V.C., Victoria I.M., Rocha S.M., Andrade D.G., Rocha A.M., Pieroni F.B., Milagres G., Purisch S., Velho G. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab 1998, 83:503-508.
15. Hayashi Y.K., Matsuda C., Ogawa M., Goto K., Tominaga K., Mitsuhashi S., Park Y.E., Nonaka I., Hino-Fukuyo N., Haginoya K., Sugano H., Nishino I. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 2009, 119:2623-2633.
16. Herbst K.L., Tannock L.R., Deeb S.S., Purnell J.Q., Brunzell J.D., Chait A. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 2003, 26:1819-1824.
17. Jackson S.N., Howlett T.A., McNally P.G., O'Rahilly S., Trembath R.C. Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy. QJM 1997, 90:27-36.
18. Hegele R.A. Premature atherosclerosis associated with monogenic insulin resistance. Circulation 2001, 103:2225-2229.
19. Semple R.K., Chatterjee V.K., O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006, 116:581-589.
20. Rubio-Cabezas O., Puri V., Murano I., Saudek V., Semple R.K., Dash S., Hyden C.S., Bottomley W., Vigouroux C., Magre J., Raymond-Barker P., Murgatroyd P.R., Chawla A., Skepper J.N., Chatterjee V.K., Suliman S., Patch A.M., Agarwal A.K., Garg A., Barroso I., Cinti S., Czech M.P., Argente J., O'Rahilly S., Savage D.B. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med 2009, 1:280-287.
21. Gandotra S., Le Dour C., Bottomley W., Cervera P., Giral P., Reznik Y., Charpentier G., Auclair M., Delepine M., Barroso I., Semple R.K., Lathrop M., Lascols O., Capeau J., O'Rahilly S., Magre J., Savage D.B., Vigouroux C. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 2011, 364:740-748.
22. Simha V., Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab 2002, 87:776-785.
23. Garg A. Clinical review#: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011, 96:3313-3325.
24. Weedon M.N., Ellard S., Prindle M.J., Caswell R., Lango Allen H., Oram R., Godbole K., Yajnik C.S., Sbraccia P., Novelli G., Turnpenny P., McCann E., Goh K.J., Wang Y., Fulford J., McCulloch L.J., Savage D.B., O'Rahilly S., Kos K., Loeb L.A., Semple R.K., Hattersley A.T. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet 2013, 45:947-950.
25. Minton J.A., Owen K.R., Ricketts C.J., Crabtree N., Shaikh G., Ehtisham S., Porter J.R., Carey C., Hodge D., Paisey R., Walker M., Barrett T.G. Syndromic obesity and diabetes: changes in body composition with age and mutation analysis of ALMS1 in 12 United Kingdom kindreds with Alstrom syndrome. J Clin Endocrinol Metab 2006, 91:3110-3116.
26. Diaz A., Vogiatzi M.G., Sanz M.M., German J. Evaluation of short stature, carbohydrate metabolism and other endocrinopathies in Bloom's syndrome. Horm Res 2006, 66:111-117.
27. Epstein C.J., Martin G.M., Schultz A.L., Motulsky A.G. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966, 45:177-221.
28. Huang-Doran I., Bicknell L.S., Finucane F.M., Rocha N., Porter K.M., Tung Y.C., Szekeres F., Krook A., Nolan J.J., O'Driscoll M., Bober M., O'Rahilly S., Jackson A.P., Semple R.K. Genetic defects in human pericentrin are associated with severe insulin resistance and diabetes. Diabetes 2011, 60:925-935.
29. Payne F., Colnaghi R., Rocha N., Seth A., Harris J., Carpenter G., Bottomley W.E., Wheeler E., Wong S., Saudek V., Savage D.B., O'Rahilly S., Carel J.-C., Barroso I., O'Driscoll M., Semple R.K. Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance. J Clin Invest. 2014, 124(9):4028-4038.
30. Kadowaki T., Bevins C.L., Cama A., Ojamaa K., Marcus-Samuels B., Kadowaki H., Beitz L., McKeon C., Taylor S.I. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 1988, 240:787-790.
31. Yoshimasa Y., Seino S., Whittaker J., Kakehi T., Kosaki A., Kuzuya H., Imura H., Bell G.I., Steiner D.F. Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 1988, 240:784-787.
32. Taylor S.I. Prenatal screening for mutations in the insulin receptor gene. How reliably does genotype predict phenotype?. J Clin Endocrinol Metab 1995, 80:1493-1495.
33. Taylor S.I., Cama A., Accili D., Barbetti F., Quon M.J., de la Luz Sierra M., Suzuki Y., Koller E., Levy-Toledano R., Wertheimer E., et al. Mutations in the insulin receptor gene. Endocr Rev 1992, 13:566-595.
34. Kadowaki T., Kadowaki H., Rechler M.M., Serrano-Rios M., Roth J., Gorden P., Taylor S.I. Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest 1990, 86:254-264.
35. Odawara M., Kadowaki T., Yamamoto R., Shibasaki Y., Tobe K., Accili D., Bevins C., Mikami Y., Matsuura N., Akanuma Y., et al. Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor. Science 1989, 245:66-68.
36. Treadway J.L., Morrison B.D., Soos M.A., Siddle K., Olefsky J., Ullrich A., McClain D.A., Pessin J.E. Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. Proc Natl Acad Sci USA 1991, 88:214-218.
37. Garg A., Wilson R., Barnes R., Arioglu E., Zaidi Z., Gurakan F., Kocak N., O'Rahilly S., Taylor S.I., Patel S.B., Bowcock A.M. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 1999, 84:3390-3394.
38. Agarwal A.K., Arioglu E., De Almeida S., Akkoc N., Taylor S.I., Bowcock A.M., Barnes R.I., Garg A. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 2002, 31:21-23.
39. Magre J., Delepine M., Khallouf E., Gedde-Dahl T., Van Maldergem L., Sobel E., Papp J., Meier M., Megarbane A., Bachy A., Verloes A., d'Abronzo F.H., Seemanova E., Assan R., Baudic N., Bourut C., Czernichow P., Huet F., Grigorescu F., de Kerdanet M., Lacombe D., Labrune P., Lanza M., Loret H., Matsuda F., Navarro J., Nivelon-Chevalier A., Polak M., Robert J.J., Tric P., Tubiana-Rufi N., Vigouroux C., Weissenbach J., Savasta S., Maassen J.A., Trygstad O., Bogalho P., Freitas P., Medina J.L., Bonnicci F., Joffe B.I., Loyson G., Panz V.R., Raal F.J., O'Rahilly S., Stephenson T., Kahn C.R., Lathrop M., Capeau J. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001, 28:365-370.
40. Simha V., Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab 2003, 88:5433-5437.
41. Antuna-Puente B., Boutet E., Vigouroux C., Lascols O., Slama L., Caron-Debarle M., Khallouf E., Levy-Marchal C., Capeau J., Bastard J.P., Magre J. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. J Clin Endocrinol Metab 2010, 95:1463-1468.
42. Haque W., Garg A., Agarwal A.K. Enzymatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acyltransferase 2 mutants associated with congenital generalized lipodystrophy. Biochem Biophys Res Commun 2005, 327:446-453.
43. Payne V.A., Grimsey N., Tuthill A., Virtue S., Gray S.L., Nora E.D., Semple R.K., O'Rahilly S., Rochford J.J. The human lipodystrophy gene BSCL2/Seipin may be essential for normal adipocyte differentiation. Diabetes 2008, 57:2055-2060.
44. Szymanski K.M., Binns D., Bartz R., Grishin N.V., Li W.P., Agarwal A.K., Garg A., Anderson R.G., Goodman J.M. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci USA 2007, 104:20890-20895.
45. Fei W., Shui G., Gaeta B., Du X., Kuerschner L., Li P., Brown A.J., Wenk M.R., Parton R.G., Yang H. Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J Cell Biol 2008, 180:473-482.
46. Boutet E., El Mourabit H., Prot M., Nemani M., Khallouf E., Colard O., Maurice M., Durand-Schneider A.M., Chretien Y., Gres S., Wolf C., Saulnier-Blache J.S., Capeau J., Magre J. Seipin deficiency alters fatty acid Delta9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie 2009, 91:796-803.
47. Ito D., Suzuki N. Molecular pathogenesis of seipin/BSCL2-related motor neuron diseases. Ann Neurol 2007, 61:237-250.
48. Magre J., Delepine M., Van Maldergem L., Robert J.J., Maassen J.A., Meier M., Panz V.R., Kim C.A., Tubiana-Rufi N., Czernichow P., Seemanova E., Buchanan C.R., Lacombe D., Vigouroux C., Lascols O., Kahn C.R., Capeau J., Lathrop M. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes 2003, 52:1573-1578.
49. Kim C.A., Delepine M., Boutet E., El Mourabit H., Le Lay S., Meier M., Nemani M., Bridel E., Leite C.C., Bertola D.R., Semple R.K., O'Rahilly S., Dugail I., Capeau J., Lathrop M., Magre J. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab 2008, 93:1129-1134.
50. Liu L., Pilch P.F. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J Biol Chem 2008, 283:4314-4322.
51. Shackleton S., Lloyd D.J., Jackson S.N., Evans R., Niermeijer M.F., Singh B.M., Schmidt H., Brabant G., Kumar S., Durrington P.N., Gregory S., O'Rahilly S., Trembath R.C. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000, 24:153-156.
52. Garg A., Vinaitheerthan M., Weatherall P.T., Bowcock A.M. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. J Clin Endocrinol Metab 2001, 86:59-65.
53. Novelli G., Muchir A., Sangiuolo F., Helbling-Leclerc A., D'Apice M.R., Massart C., Capon F., Sbraccia P., Federici M., Lauro R., Tudisco C., Pallotta R., Scarano G., Dallapiccola B., Merlini L., Bonne G. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002, 71:426-431.
54. Vantyghem M.C., Pigny P., Maurage C.A., Rouaix-Emery N., Stojkovic T., Cuisset J.M., Millaire A., Lascols O., Vermersch P., Wemeau J.L., Capeau J., Vigouroux C. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 2004, 89:5337-5346.
55. Young J., Morbois-Trabut L., Couzinet B., Lascols O., Dion E., Bereziat V., Feve B., Richard I., Capeau J., Chanson P., Vigouroux C. Type A insulin resistance syndrome revealing a novel lamin A mutation. Diabetes 2005, 54:1873-1878.
56. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
57. Agostini M., Schoenmakers E., Mitchell C., Szatmari I., Savage D., Smith A., Rajanayagam O., Semple R., Luan J., Bath L., Zalin A., Labib M., Kumar S., Simpson H., Blom D., Marais D., Schwabe J., Barroso I., Trembath R., Wareham N., Nagy L., Gurnell M., O'Rahilly S., Chatterjee K. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab 2006, 4:303-311.
58. Al-Shali K., Cao H., Knoers N., Hermus A.R., Tack C.J., Hegele R.A. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J Clin Endocrinol Metab 2004, 89:5655-5660.
59. Vantyghem M.C., Balavoine A.S., Douillard C., Defrance F., Dieudonne L., Mouton F., Lemaire C., Bertrand-Escouflaire N., Bourdelle-Hego M.F., Devemy F., Evrard A., Gheerbrand D., Girardot C., Gumuche S., Hober C., Topolinski H., Lamblin B., Mycinski B., Ryndak A., Karrouz W., Duvivier E., Merlen E., Cortet C., Weill J., Lacroix D., Wemeau J.L. How to diagnose a lipodystrophy syndrome. Ann Endocrinol (Paris) 2012, 73:170-189.
60. Misra A., Peethambaram A., Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004, 83:18-34.
61. Agostini M., Gurnell M., Savage D.B., Wood E.M., Smith A.G., Rajanayagam O., Garnes K.T., Levinson S.H., Xu H.E., Schwabe J.W., Willson T.M., O'Rahilly S., Chatterjee V.K. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 2004, 145:1527-1538.
62. Javor E.D., Cochran E.K., Musso C., Young J.R., Depaoli A.M., Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005, 54:1994-2002.